Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia

Clinical Infectious Diseases

Volumn 60, Issue 9, 2015, Pages 1319-1325

  Tamma, Pranita D ^a   Han, Jennifer H ^b   Rock, Clare ^c   Harris, Anthony D ^c   Lautenbach, Ebbing ^b   Hsu, Alice J ^d   Avdic, Edina ^d   Cosgrove, Sara E ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Carbapenem; ESBL; Gram negative; Piperacillin tazobactam; Resistance

Indexed keywords

CARBAPENEM; CEPHALOSPORIN DERIVATIVE; CILASTATIN PLUS IMIPENEM; CLAVULANIC ACID; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA LACTAMASE INHIBITOR; CARBAPENEM DERIVATIVE; PENICILLANIC ACID; PIPERACILLIN; PIPERACILLIN, TAZOBACTAM DRUG COMBINATION;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; CONTROLLED STUDY; ENZYME SYNTHESIS; FEMALE; HAZARD RATIO; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; PRIORITY JOURNAL; PROPENSITY SCORE; SURVIVAL; AGED; ANALOGS AND DERIVATIVES; COHORT ANALYSIS; COMPARATIVE STUDY; DRUG EFFECTS; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; ISOLATION AND PURIFICATION; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; METABOLISM; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PROTEUS MIRABILIS; SURVIVAL RATE; TIME FACTOR;

AGED; ANTI-BACTERIAL AGENTS; BACTEREMIA; BETA-LACTAMASE INHIBITORS; BETA-LACTAMASES; CARBAPENEMS; COHORT STUDIES; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; FEMALE; HUMANS; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PENICILLANIC ACID; PIPERACILLIN; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROTEUS MIRABILIS; SURVIVAL RATE; TIME FACTORS;

EID: 84928879624     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ003     Document Type: Article

References (31)

1. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-64.
2. Endimiani A, Luzzaro F, Brigante G, et al. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother 2005; 49:2598-605.
3. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsi-ella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemo-ther 2004; 48:4574-81.
4. Tamma PD, Savard P, Pal T, Sonnevend A, Perl TM, Milstone AM. An outbreak of extended-spectrum beta-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2012; 33:631-4.
5. Menashe G, Borer A, Yagupsky P, et al. Clinical significance and impact on mortality of extended-spectrum beta lactamase-producing Entero-bacteriaceae isolates in nosocomial bacteremia. Scand J Infect Dis 2001; 33:188-93.
6. Paterson DL, Ko WC, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
7. Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapene-mase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943-50.
8. Anderson DJ, Engemann JJ, Harrell LJ, Carmeli Y, Reller LB, Kaye KS. Predictors of mortality in patients with bloodstream infection due to ceftazidime-resistant Klebsiella pneumoniae. Antimicrob Agents Che-mother 2006; 50:1715-20.
9. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lauten-bach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing En-terobacteriaceae: variability by site of infection. Arch Intern Med 2005; 165:1375-80.
10. Perez F, Bonomo RA. Can we really use β-lactam/β-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum β-lactamase-producing bacteria? Clin Infect Dis 2012; 54:175-7.
11. Paterson DL, Ko WC, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin Infect Dis 2004; 39:31-7.
12. Hsu AJ, Tamma PD. The treatment of multi-drug resistant gram-negative infections in children. Clin Infect Dis 2014; 58:1439-48.
13. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enter-obacteriaceae producing extended-spectrum beta-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:2793-803.
14. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Car-bapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30:666-71.
15. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106.
16. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-86.
17. Marchaim D, Sunkara B, Lephart PR, et al. Extended-spectrum beta-lactamase producers reported as susceptible to piperacillin-tazobactam, cefepime, and cefuroxime in the era of lowered breakpoints and no confirmatory tests. Infect Control Hosp Epidemiol 2012; 33:853-5.
18. Chen YH, Hsueh PR, Badal RE, et al. Antimicrobial susceptibility profiles of aerobic and facultative gram-negative bacilli isolated from patients with intra-abdominal infections in the Asia-Pacific region according to currently established susceptibility interpretive criteria. J Infect 2011; 62:280-91.
19. Hoban DJ, Lascols C, Nicolle LE, et al. Antimicrobial susceptibility of Enterobacteriaceae, including molecular characterization of extended-spectrum beta-lactamase-producing species, in urinary tract isolates from hospitalized patients in North America and Europe: results from the SMART study 2009-2010. Diagn Microbiol Infect Dis 2012; 74:62-7.
20. Tamma PD, Girdwood SC, Gopaul R, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis 2013; 57:781-8.
21. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; approved standard. Twenty-fourth informational supplement. CLSI document M100-S24. Wayne, PA: CLSI, 2014.
22. Lautenbach E, Patel JB, Bilker WB, Edelstein PH, Fishman NO. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis 2001; 32:1162-71.
23. Han JH, Nachamkin I, Zaoutis TE, et al. Risk factors for gastrointestinal tract colonization with extended-spectrum beta-lactamase (ESBL)-pro-ducing Escherichia coli and Klebsiella species in hospitalized patients. Infect Control Hosp Epidemiol 2012; 33:1242-5.
24. Harris AD, McGregor JC, Johnson JA, et al. Risk factors for colonization with extended-spectrum beta-lactamase-producing bacteria and intensive care unit admission. Emerg Infect Dis 2007; 13:1144-9.
25. Thomson KS, Moland ES. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2001; 45:3548-54.
26. Lopez-Cerero L, Picon E, Morillo C, et al. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates. Clin Microbiol Infect 2010; 16:132-6.
27. Rodríguez-Baño J, Navarro MD, Retamar P, Picon E, Pascual A. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis 2012; 54:167-74.
28. Schoonover LL, Occhipinti DJ, Rodvold KA, Danziger LH. Piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination. Ann Pharmacother 1995; 29:501-14.
29. US Food and Drug Administration. Zosyn (piperacillin and tazobac-tam for injection). Available at: http://www.fda.gov/ohrms/dockets/dockets/06p0195/06P-0195-EC1-Attach-1.pdf. Accessed 19 September 2014.
30. Dudley MN, Ambrose PG, Bhavnani SM, Craig WA, Ferraro MJ, Jones RN. Background and rationale for revised clinical and laboratory standards institute interpretive criteria (breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and aztreonam. Clin Infect Dis 2013; 56:1301-9.
31. Hoban DJ, Bouchillon SK, Hawser SP, Badal RE, Labombardi VJ, Di-Persio J. Susceptibility of gram-negative pathogens isolated from patients with complicated intra-abdominal infections in the United States, 2007-2008: results of the Study for Monitoring Antimicrobial Resistance Trends (SMART). Antimicrob Agents Chemother 2010; 54:3031-4.